Sellas Life Sciences Group Inc (SLS) FinancialsSLSFinancialSellas Life Sciences Group Inc

Evaluating the bottom line, Sellas Life Sciences Group Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.63%, provide a clear picture of how effectively SLS converts its operational activities into shareholder value.

In the context of the broader market, SLS competes directly with industry leaders such as ATAI and VRDN. With a market capitalization of $2.67B, it holds a significant position in the sector. When comparing efficiency, SLS's gross margin of N/A stands against ATAI's 100.00% and VRDN's 100.00%. Such benchmarking helps identify whether Sellas Life Sciences Group Inc is trading at a premium or discount relative to its financial performance.

The company has shown a remarkable year-over-year change of +621.86%, indicating strong growth in stock performance, despite ongoing net losses.